Literature DB >> 9305663

Diagnostic tests for hepatitis C.

D R Gretch1.   

Abstract

Diagnostic tests for hepatitis C can be divided into the following two general categories: 1) serological assays that detect antibody to hepatitis C virus (anti-HCV); and 2) molecular assays that detect, quantify, and/or characterize HCV RNA genomes within an infected patient. Serological assays have been subdivided into screening tests for anti-HCV, such as the enzyme immunoassay (EIA), and supplemental tests such as the recombinant immunoblot assay (RIBA). Three generations of anti-HCV tests have been developed, and each generation has resulted in an improvement in the sensitivity of detecting anti-HCV. Supplemental anti-HCV tests are designed to resolve false-positive testing by EIA, and are appropriately used in low-prevalence settings in which false-positive anti-HCV tests remain a problem. Third-generation anti-HCV tests (EIA-3 and RIBA-3, respectively) contain antigens from the HCV core, nonstructural 3, nonstructural 4, and nonstructural 5 genes. Detection of HCV RNA in patient specimens by polymerase chain reaction (PCR) provides evidence of active HCV infection and is potentially useful for confirming the diagnosis and monitoring the antiviral response to therapy. Optimal HCV PCR assays at present have a sensitivity of less than 100 copies of HCV RNA per milliliter of plasma or serum. Standardization and proficiency testing of diagnostic laboratories performing HCV PCR remains an important problem for future study. Two main technologies exist for assessing HCV RNA levels or viral load. Quantitative PCR is the most sensitive test for determining hepatitis C viral load, whereas the branched-chain DNA test appears to be the most precise method. Major limitations of the current tests are inadequate dynamic range and high variability of PCR-based assays, and poor sensitivity of the branched-chain DNA test. Molecular tests have also been developed to classify HCV into distinct genotypes; the clinical importance of HCV genotype determination remains a subject for future investigation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305663     DOI: 10.1002/hep.510260708

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

1.  Diagnostic value of anti-hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation.

Authors:  C Casino; D Lilli; D Rivanera; A Comanducci; M Rossi; G Casciaro; I Pecorella; D Alfani; C Mancini
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

Review 2.  Laboratory assays for diagnosis and management of hepatitis C virus infection.

Authors:  Sandra S Richter
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

3.  Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination.

Authors:  G Gerken; T Rothaar; M G Rumi; R Soffredini; M Trippler; M J Blunk; A Butcher; S Soviero; G Colucci
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Case-reporting of acute hepatitis B and C among injection drug users.

Authors:  Holly Hagan; Nadine Snyder; Eileen Hough; Tianji Yu; Shelly McKeirnan; Janice Boase; Jeffrey Duchin
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

5.  Hepatitis C virus quantitation: optimization of strategies for detecting low-level viremia.

Authors:  W T Hofgärtner; J A Kant; K E Weck
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 6.  HIV/HCV coinfection: management update.

Authors:  Daniel Alvarez
Journal:  J Natl Med Assoc       Date:  2004-02       Impact factor: 1.798

7.  Hepatitis A, B, and C.

Authors:  R Gilson; M G Brook
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

8.  Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis.

Authors:  Max Trubnikov; Ping Yan; Jane Njihia; Chris Archibald
Journal:  CMAJ Open       Date:  2014-10-01

9.  Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA.

Authors:  J T Stapleton; D Klinzman; W N Schmidt; M A Pfaller; P Wu; D R LaBrecque; J q Han; M J Phillips; R Woolson; B Alden
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Evaluation of Quantitative Real-Time PCR as a Hepatitis C Virus Supplementary Test After RIBA Discontinuation.

Authors:  Shunyou Gong; Christine L Schmotzer; Lan Zhou
Journal:  J Clin Lab Anal       Date:  2015-10-26       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.